Imugene - Charts & Price Action (New thread), page-473

Hi all, have just stumbled across IMU and am trawling through the many threads, looks great on the surface however one thing i cant seem to soften and hoping people can help with is the clinical risk, is it all just early days pipeline stuff?

Looks like HER-Vaxx phase 3 won't be able to start until optimistically Q3 2022 and would probably need to run for 24 months. So perhaps Q4 2024 for Phase 3 readouts and then another 12 months for approval application.

According to their latest presentation, the Phase 2 trial for CF33 won't start until Q2 2022 and will need to run for 24 months. So that means early 2025 at the earliest to start a Phase 3 trial that will be needed for approval ( assume another 24 - 36 months before an approval application can be submitted, nominally 2027 at the earliest ).

I guess IMU is aiming for a buyout occurring on the back of Phase 1 & 2 trials but the clinical risk for IMU to get to this point very high.